Exacerbation of Infliximab-Induced Paradoxical Psoriasis After Ustekinumab Therapy

Journal of Dermatology - United States
doi 10.1111/1346-8138.13803
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Ustekinumab-Induced Remission of Recalcitrant Guttate Psoriasis: A Case Series

JAAD Case Reports
Dermatology
2017English

Effectiveness of Resuming Ustekinumab Therapy in Psoriasis Patients With Metabolic Disorders. Clinical Experience

Vestnik dermatologii i venerologii
2019English

Risankizumab vs. Ustekinumab for Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2019English

Paradoxical Response During Antituberculous Therapy in a Patient Discontinuing Infliximab: A Case Report

Journal of Medical Case Reports
Medicine
2009English

Psoriasis: Therapie Mit Ustekinumab Ist Langzeitig Erfolgreich

hautnah dermatologie
2013English

Treatment of Severe Psoriasis With Infliximab

Therapeutics and Clinical Risk Management
2008English

Successful Treatment of Juvenile Generalized Pustular Psoriasis With Infliximab Therapy: Two Case Reports

Journal of International Medical Research
BiochemistryMedicineCell Biology
2020English

Infliximab for the Treatment of Plaque Psoriasis

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Risankizumab Versus Ustekinumab for Plaque Psoriasis: A Critical Appraisal

British Journal of Dermatology
DermatologyMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy